We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

The Effect of Alcohol on ABCA1 Expression and Lipid Metabolism

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00558935
Recruitment Status : Terminated (It was found that 20g of alcohol daily had no effect on ABCA1 expression or HDL levels.)
First Posted : November 16, 2007
Last Update Posted : May 10, 2011
Information provided by:
Bayside Health

Brief Summary:
The purpose of this study is to investigate the effects of red wine on ABCA1 levels

Condition or disease Intervention/treatment
Type 2 Diabetes Heart Disease Dietary Supplement: Red Wine

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Prevention
Study Start Date : October 2007
Primary Completion Date : October 2008
Study Completion Date : December 2008

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Intervention Details:
    Dietary Supplement: Red Wine
    20g alcohol daily/red wine for 4 weeks

Primary Outcome Measures :
  1. measurements of dyslipidemia [ Time Frame: 2 years ]

Secondary Outcome Measures :
  1. lipid functionality [ Time Frame: 2 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy participants
  • Aged 18-65 years
  • Free of overt coronary disease
  • BMI < 35
  • Fasting plasma glucose <6.1 mmol
  • Unmedicated
  • No major illness

Exclusion Criteria:

  • Unable to give informed consent
  • Smokers
  • Participants with alcoholism

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00558935

Australia, Victoria
Baker Heart Research Institute
Melbourne, Victoria, Australia, 3004
Sponsors and Collaborators
Bayside Health
Principal Investigator: Bronwyn A Kingwell, PhD Baker Heart Research Institute

ClinicalTrials.gov Identifier: NCT00558935     History of Changes
Other Study ID Numbers: 24/06
First Posted: November 16, 2007    Key Record Dates
Last Update Posted: May 10, 2011
Last Verified: May 2011

Additional relevant MeSH terms:
Heart Diseases
Cardiovascular Diseases